Tumor Biology

, Volume 36, Issue 12, pp 9903–9908 | Cite as

Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma

  • Shudan Mao
  • Wenqi Yang
  • Limei Ai
  • Zhe Li
  • Jieping Jin
Research Article


The objective of this study was to investigate the expression and significance of the transforming growth factor β type II receptor (TGFβRII) in diffuse large B cell lymphoma. All patients were enrolled at the First Affiliated Hospital of Liaoning Medical University between 2001 and 2007. The median follow-up period was 53.3 months. Of the 338 patients studied, 131 (38.76 %) had TGFβRII positive expression on immunohistochemistry. The 5 year survival rate was significantly higher in patients with TGFβRII expression than in those without TGFβRII expression (40.3 vs. 31.6 %, P = 0.041). Multivariate analysis identified TGFβRII expression as an independent predictive parameter for survival, in addition to lactate dehydrogenase, clinical stage, and histologic subtype. TGFβRII expression may be considered a new prognostic factor of diffuse large B cell lymphoma.


Diffuse large B cell lymphoma Survival TGFβRII 


Compliance with Ethical Standards

Conflicts of interest


Informed consent

The study protocol was approved by the Ethics Committee of Liaoning Medical University, and written informed consent was obtained from all participants involved in the study.

Authors’ contributions

Shudan Mao and Wenqi Yang conducted the experiments and drafted the manuscript. Zhe Li and Limei Ai participated in the design of the study and performed the statistical analysis. Jieping Jin conceived the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.


  1. 1.
    Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues (edition 4). Lyon: International Agency for Research on Cancer Press; 2008.Google Scholar
  2. 2.
    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–95.CrossRefPubMedGoogle Scholar
  3. 3.
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.PubMedGoogle Scholar
  4. 4.
    Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol. 1999;111:S8–S12.PubMedGoogle Scholar
  5. 5.
    Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d’Etudes des Lymphomes Agressifs. J Clin Oncol. 1991;9:211–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 1996;87:265–72.PubMedGoogle Scholar
  7. 7.
    Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a populationbased study. J Clin Oncol. 1996;14:2131–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin’s lymphoma: a British National Lymphoma Investigation Study. Blood. 1996;88:1046–51.PubMedGoogle Scholar
  9. 9.
    Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997;90:244–51.PubMedGoogle Scholar
  10. 10.
    Koduru PR, Raju K, Vadmal V, et al. Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin’s lymphoma. Blood. 1997;90:4078–91.PubMedGoogle Scholar
  11. 11.
    Ichikawa A, Kinoshita T, Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med. 1997;337:529–34.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhang H, Gao J, Zhao Z, Li M, Liu C. Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: a prospective, observational study. BMC Cancer. 2014;14:333.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Liu C, Lu Y, Wang B-b, Zhang Y-j, Zhang R-s, Lu Y, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253:1165–71.CrossRefPubMedGoogle Scholar
  14. 14.
    Liu C, Cao X, Zhang Y, Xu H, Zhang R, Wu Y, et al. Co-expression of Oct-4 and Nestin in human breast cancers. Mol Biol Rep. 2012;39:5875–81.CrossRefPubMedGoogle Scholar
  15. 15.
    Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H, et al. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One. 2012;7(10):e46670.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hao Zhang, Yuan Ren, Huanming Xu, Deyan Pang, Chao Duan, Caigang Liu. The expression of stem cell protein Piwil2 and piR-932 in breast cancer. 2013 Aug 27. pii: S0960-7404(13)00066-2.Google Scholar
  17. 17.
    Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet. 1995;9:48.CrossRefPubMedGoogle Scholar
  18. 18.
    Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 1996;56:4836.PubMedGoogle Scholar
  19. 19.
    Umar A, Boyer JC, Thomas DC, Nguyen DC, Risinger JI, Boyd J, et al. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem. 1994;269:14367.PubMedGoogle Scholar
  20. 20.
    Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, et al. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res. 1995;55:6063.PubMedGoogle Scholar
  21. 21.
    Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair defective human tumor cell lines. Cancer Res. 1997;57:808.PubMedGoogle Scholar
  22. 22.
    Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95:6870.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, et al. hMLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet. 1999;8:661.CrossRefPubMedGoogle Scholar
  24. 24.
    Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336.CrossRefPubMedGoogle Scholar
  25. 25.
    Yamamoto H, Sawai H, Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1997;57:4420.PubMedGoogle Scholar
  26. 26.
    Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997;275:967.CrossRefPubMedGoogle Scholar
  27. 27.
    Schwartz Jr S, Yamamoto H, Navarro M, Maestro M, Reventos J, Perucho M. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1999;59:2995.PubMedGoogle Scholar
  28. 28.
    Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292–3.CrossRefPubMedGoogle Scholar
  29. 29.
    Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, et al. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res. 2007;27:543–52.CrossRefPubMedGoogle Scholar
  30. 30.
    Santibanez JF, Quintanilla M, Bernabeu C. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2011;121:233–51.CrossRefGoogle Scholar
  31. 31.
    Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 1992;71:1003–14.CrossRefPubMedGoogle Scholar
  32. 32.
    Derynck R, Zhang Y. Smad-dependent and Smad-independent pathways in TGF-family signalling. Nature. 2003;425:577–84.CrossRefPubMedGoogle Scholar
  33. 33.
    Reiss M. TGF-beta and cancer. Microbes Infect. 1999;1:1327–47.CrossRefPubMedGoogle Scholar
  34. 34.
    Rehmann JA, LeBien TW. Transforming growth factorbeta regulates normal human pre-Bcell differentiation. Int Immunol. 1994;6:315–22.CrossRefPubMedGoogle Scholar
  35. 35.
    Kehrl JH, Thevenin C, Rieckmann P, et al. Transforming growth factor-beta suppresses human Blymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J Immunol. 1991;146:4016–23.PubMedGoogle Scholar
  36. 36.
    Smeland EB, Blomhoff HK, Holte H, et al. Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human Blymphocytes. Exp Cell Res. 1987;171:213–22.CrossRefPubMedGoogle Scholar
  37. 37.
    Bouchard C, Fridman WH, Sautes C. Effect of TGF-beta1 on cell cycle regulatory proteins in LPS-stimulated normal mouse Blymphocytes. J Immunol. 1997;159:4155–64.PubMedGoogle Scholar
  38. 38.
    Djaborkhel R, Tvrdik D, Eckschlager T, et al. Cyclin A down-regulation in TGFbeta1-arrested follicular lymphoma cells. Exp Cell Res. 2000;261:250–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Kehrl JH, Roberts AB, Wakefield LM, et al. Transforming growth factor beta is an important immunomodulatory protein for human Blymphocytes. J Immunol. 1986;137:3855–60.PubMedGoogle Scholar
  40. 40.
    Wahl SM, Hunt DA, Wong HL, et al. Transforming growth factor is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol. 1988;140:3026–32.PubMedGoogle Scholar
  41. 41.
    Ranges GE, Figari IS, Espevik T, et al. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987;166:991–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia Bcells. J Exp Med. 1994;179:999–1004.CrossRefPubMedGoogle Scholar
  43. 43.
    Lebman DA, Edmiston JS. The role of TGF-beta in growth, differentiation, and maturation of Blymphocytes. Microbes Infect. 1999;1:1297–304.CrossRefPubMedGoogle Scholar
  44. 44.
    Chaouchi N, Arvanitakis L, Auffredou MT, et al. Characterization of transforming growth factor-beta 1 induced apoptosis in normal human Bcells and lymphoma Bcell lines. Oncogene. 1995;11:1615–22.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Shudan Mao
    • 1
  • Wenqi Yang
    • 2
  • Limei Ai
    • 1
  • Zhe Li
    • 1
  • Jieping Jin
    • 1
  1. 1.Department of HematologyThe First Affiliated Hospital of Liaoning Medical UniversityJinzhouChina
  2. 2.Department of CardiologyThe First Affiliated Hospital of Liaoning Medical UniversityJinzhouChina

Personalised recommendations